At the molecular level, miR-185-5p decreased the expressions of lipid metabolism-related genes via inhibiting SREBP-2 activation thus confirming the critical role of miR-185-5p for clinic use as a lipid-regulating agent in treating arteriosclerosis and related lipid metabolism disorders. This evidence concerns the gene SREBF2 and arteriosclerosis disorder.